Diagnostic ultrasound ( PDFDrive )

1114 PART IV Obstetric and Fetal Sonography
212. Joergensen MW, Niemann I, Rasmussen AA, et al. Triploid pregnancies:
genetic and clinical features of 158 cases. Am J Obstet Gynecol.
2014;211(4):370 e1-370 e19.
213. McFadden DE, Robinson WP. Phenotype of triploid embryos. J Med Genet.
2006;43(7):609-612.
214. Jauniaux E, Brown R, Rodeck C, Nicolaides KH. Prenatal diagnosis of
triploidy during the second trimester of pregnancy. Obstet Gynecol.
1996;88(6):983-989.
215. Jauniaux E, Brown R, Snijders RJ, et al. Early prenatal diagnosis of triploidy.
Am J Obstet Gynecol. 1997;176(3):550-554.
216. Rijhsinghani A, Yankowitz J, Strauss RA, et al. Risk of preeclampsia in
second-trimester triploid pregnancies. Obstet Gynecol. 1997;90(6):
884-888.
217. Goldstein DP, Berkowitz RS. Current management of complete and partial
molar pregnancy. J Reprod Med. 1994;39(3):139-146.
218. Baena N, De Vigan C, Cariati E, et al. Turner syndrome: evaluation of
prenatal diagnosis in 19 European registries. Am J Med Genet A.
2004;129A(1):16-20.
219. Wax JR, Blakemore KJ, Baser I, Stetten G. Isolated fetal ascites detected by
sonography: an unusual presentation of Turner syndrome. Obstet Gynecol.
1992;79(5 Pt 2):862-863.
220. Azar GB, Snijders RJ, Gosden C, Nicolaides KH. Fetal nuchal cystic
hygromata: associated malformations and chromosomal defects. Fetal Diagn
her. 1991;6(1-2):46-57.
221. Papp C, Beke A, Mezei G, et al. Prenatal diagnosis of Turner syndrome:
report on 69 cases. J Ultrasound Med. 2006;25(6):711-717.
222. American College of Obstetricians and Gynecologists. Cell-free DNA
screening for fetal aneuploidy. Practice Bulletin. 2015;No. 640.
223. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy
detection by maternal plasma DNA sequencing. Obstet Gynecol.
2012;119(5):890-901.
224. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy
testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of
polymorphic loci. Prenat Diagn. 2012;32(13):1233-1241.
225. Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection and
selective analysis of cell-free DNA obtained from maternal blood: evaluation
for trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206(4):319.e1-
319.e9.
226. Gil MM, Quezada MS, Revello R, et al. Analysis of cell-free DNA in maternal
blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound
Obstet Gynecol. 2015;45(3):249-266.
227. Cuckle H, Benn P, Pergament E. Cell-free DNA screening for fetal aneuploidy
as a clinical service. Clin Biochem. 2015;48(15):932-941.
228. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard
prenatal aneuploidy screening. N Engl J Med. 2014;370(9):799-808.
229. Pergament E, Cuckle H, Zimmermann B, et al. Single-nucleotide
polymorphism-based noninvasive prenatal screening in a high-risk and
low-risk cohort. Obstet Gynecol. 2014;124(2 Pt 1):210-218.
230. Ashoor G, Syngelaki A, Poon LC, et al. Fetal fraction in maternal plasma
cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal
characteristics. Ultrasound Obstet Gynecol. 2013;41(1):26-32.
231. Bevilacqua E, Gil MM, Nicolaides KH, et al. Performance of screening for
aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies.
Ultrasound Obstet Gynecol. 2015;45(1):61-66.
232. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for
noninvasive examination of trisomy. N Engl J Med. 2015;372(17):
1589-1597.
233. Petersen OB, Vogel I, Ekelund C, et al. Potential diagnostic consequences
of applying non-invasive prenatal testing: population-based study from a
country with existing irst-trimester screening. Ultrasound Obstet Gynecol.
2014;43(3):265-271.
234. Norton ME, Jellife-Pawlowski LL, Currier RJ. Chromosome abnormalities
detected by current prenatal screening and noninvasive prenatal testing.
Obstet Gynecol. 2014;124(5):979-986.
235. Benachi A, Letourneau A, Kleininger P, et al. Cell-free DNA analysis in
maternal plasma in cases of fetal abnormalities detected on ultrasound
examination. Obstet Gynecol. 2015;125(6):1330-1337.
236. Shani H, Goldwaser T, Keating J, Klugman S. Chromosomal abnormalities
not currently detected by cell-free fetal DNA: a retrospective analysis at a
single center. Am J Obstet Gynecol. 2016;214(6):729.e1-3729.e11.
237. Hillman SC, McMullan DJ, Hall G, et al. Use of prenatal chromosomal
microarray: prospective cohort study and systematic review and metaanalysis.
Ultrasound Obstet Gynecol. 2013;41(6):610-620.
238. Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus
karyotyping for prenatal diagnosis. N Engl J Med. 2012;367(23):
2175-2184.
239. Drury S, Williams H, Trump N, et al. Exome sequencing for prenatal diagnosis
of fetuses with sonographic abnormalities. Prenat Diagn. 2015;35(10):
1010-1017.
240. van den Berg C, Van Opstal D, Brandenburg H, et al. Accuracy of abnormal
karyotypes ater the analysis of both short- and long-term culture of chorionic
villi. Prenat Diagn. 2000;20(12):956-969.
241. Aina-Mumuney A, Wood ED, Corson VL, et al. Clinical consequences of
an increasing trend of preferential use of cultured villi for molecular diagnosis
by CVS. Prenat Diagn. 2008;28(4):332-334.
242. Ledbetter DH, Zachary JM, Simpson JL, et al. Cytogenetic results from the
U.S. Collaborative Study on CVS. Prenat Diagn. 1992;12(5):317-345.
243. Hahnemann JM, Vejerslev LO. Accuracy of cytogenetic indings on chorionic
villus sampling (CVS)—diagnostic consequences of CVS mosaicism and
non-mosaic discrepancy in centres contributing to EUCROMIC 1986-1992.
Prenat Diagn. 1997;17(9):801-820.
244. Brun JL, Mangione R, Gangbo F, et al. Feasibility, accuracy and safety of
chorionic villus sampling: a report of 10741 cases. Prenat Diagn.
2003;23(4):295-301.
245. Evans MI, Andriole S, Evans SM. Genetics: update on prenatal screening
and diagnosis. Obstet Gynecol Clin North Am. 2015;42(2):193-208.
246. Wolstenholme J. Conined placental mosaicism for trisomies 2, 3, 7, 8, 9,
16, and 22: their incidence, likely origins, and mechanisms for cell lineage
compartmentalization. Prenat Diagn. 1996;16(6):511-524.
247. Grati FR, Bajaj K, Malvestiti F, et al. he type of feto-placental aneuploidy
detected by cfDNA testing may inluence the choice of conirmatory
diagnostic procedure. Prenat Diagn. 2015;35(10):994-998.
248. Akolekar R, Beta J, Picciarelli G, et al. Procedure-related risk of miscarriage
following amniocentesis and chorionic villus sampling: a systematic review
and meta-analysis. Ultrasound Obstet Gynecol. 2015;45(1):16-26.
249. Lippman A, Tomkins DJ, Shime J, Hamerton JL. Canadian multicentre
randomized clinical trial of chorion villus sampling and amniocentesis.
Final report. Prenat Diagn. 1992;12(5):385-408.
250. Caughey AB, Hopkins LM, Norton ME. Chorionic villus sampling compared
with amniocentesis and the diference in the rate of pregnancy loss. Obstet
Gynecol. 2006;108(3 Pt 1):612-616.
251. Firth HV, Boyd PA, Chamberlain P, et al. Severe limb abnormalities ater
chorion villus sampling at 56-66 days’ gestation. Lancet. 1991;337(8744):
762-763.
252. Froster UG, Jackson L. Limb defects and chorionic villus sampling:
results from an international registry, 1992-94. Lancet. 1996;347(9000):
489-494.
253. World Health Organization WHO/PAHO consultation on CVS. Evaluation
of chorionic villus sampling safety. Prenat Diagn. 1999;19(2):97-99.
254. American College of Obstetricians and Gynecologists. ACOG Practice
Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy.
Obstet Gynecol. 2007;110(6):1459-1467.
255. Borgida AF, Mills AA, Feldman DM, et al. Outcome of pregnancies
complicated by ruptured membranes ater genetic amniocentesis. Am J
Obstet Gynecol. 2000;183(4):937-939.
256. Devlieger R, Millar LK, Bryant-Greenwood G, et al. Fetal membrane healing
ater spontaneous and iatrogenic membrane rupture: a review of current
evidence. Am J Obstet Gynecol. 2006;195(6):1512-1520.